Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
glaxosmithkline
5
×
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
5
×
new york blog main
5
×
new york top stories
raleigh-durham blog main
5
×
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
startups
5
×
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alzheimer's disease
cancer
clinical trials
deals
eli lilly
merck
abbvie
amgen
biogen
bristol-myers squibb
cancer immunotherapy
What
bio
5
×
roundup
black
companies
crispr
diamond’s
drug
acquisitions
albert
alliance
appetite
approval
biggest
biogen’s
biopharmaceutical
bourla
bread
bristol
butter
buy
buyout
calls
cancer
cash
ceo
changing
color
company
continue
convo
days
debut
diabetes
diamond
drugs
earlier
eli
failures
future
giant
Language
unset
unknown
Current search:
glaxosmithkline
×
startups
×
" national top stories "
×
bio
×
" new york blog main "
×
" raleigh-durham blog main "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More